| Management of patients with multiple myeloma during COVID-19 lockdown |
| Received:July 24, 2022 Revised:October 18, 2022 Click here to download the full text |
| Citation of this paper:YANG Xue,CHENG Lu-ya,CHEN Chen,KE Yang,GU Shi-yang,SHI Miao-jie,ZHANG Xue-jiao,GAO Ru-pan,CHEN Fei-fei,LIU Peng.Management of patients with multiple myeloma during COVID-19 lockdown[J].Chinese Journal of Clinical Medicine,2022,29(6):945-949 |
| Hits: 1189 |
| Download times: 238 |
| Author Name | Affiliation | E-mail | | YANG Xue | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHENG Lu-ya | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHEN Chen | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | KE Yang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | GU Shi-yang | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SHI Miao-jie | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | ZHANG Xue-jiao | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | GAO Ru-pan | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHEN Fei-fei | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LIU Peng | Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | liu.peng@zs-hospital.sh.cn |
|
| Abstract:Objective To analyze management strategies and therapeutic responses of patients with multiple myeloma (MM) during COVID-19 lockdown. Methods Baseline clinical data and management information of 267 patients diagnosed with MM treated at Zhongshan Hospital, Fudan University during Shanghai lockdown from March 28 to June 1, 2022, were retrospectively analyzed. Responses before and after lockdown were evaluated and compared. Results 161 native and 106 non-native MM patients were included. 77.0% and 16.1% of native patients came to outpatient and inpatient clinic of our hospital, respectively. 76.4% of non-native patients went to local hospital for treatment. Follow-up was mostly completed via WeChat (90.0%) or telephone (9.0%). During lockdown, 70.8% of the patients continued treatment with the original regimen. 25.1% of the patients extended treatment interval, mainly lowering the frequency of intravenous daratumumab and subcutaneous bortezomib injection. Due to disease progression, 4.1% of the patients changed treatment regimens. Besides, 7 patients discontinued treatment due to COVID-19 infection, accounting for 2.6% of all patients. In contrast to a fully oral treatment combination, more patients administered with injection-containing regimen extended treatment intervals (37.0% vs 10.8%). After comparing responses of 183 evaluable patients before and after the city lockdown, found that 94.5% of patients achieved better response or maintained the best response achieved. Conclusion Considering the virus susceptibility related to immunodeficiency in MM patients as well as less accessibility to hospitalization during COVID-19 epidemic, effective management of MM patients in the context of regular epidemic prevention and control remains an important challenge. Providing early patient education, increasing the proportion of outpatient treatment, eliciting fully oral regimens for appropriate patients, and performing follow-up management via new medium may become effective coping strategies against emergency lockdown. |
| keywords:multiple myeloma COVID-19 pandemic lockdown patient management |
| HTML View Full Text View/Add Comment Download reader |
|
|
|